NY-PHILIP-MORRIS-INTL
17.6.2021 13:02:08 CEST | Business Wire | Press release
Jacek Olczak, Chief Executive Officer of Philip Morris International (PMI) (NYSE: PM), today announced a new structure for the Americas with the appointment of Deepak Mishra—formerly Chief Strategy Officer—as President, Americas Region, covering the United States, Canada, and Latin America. The appointment is effective July 1.
The new structure in the Americas will focus on three areas: strengthening PMI’s leadership in Latin America & Canada as the company accelerates toward a smoke-free future; deepening efforts with partners to commercialize reduced risk products in the U.S.; and building a vital launchpad for the company’s “beyond nicotine” strategy in the U.S., in coordination with PMI’s Life Sciences group, through expanded partnerships and commercial deployment.
Mr. Olczak said, “I am thrilled to name Deepak Mishra, one of our top business leaders, to one of the most important roles for the future of our company. In less than three years with PMI, he has been instrumental in shaping our long-term strategy and bringing it to life through strategic partnerships and investments. Deepak brings to the role deep expertise in mergers and acquisitions, a likely component of our beyond nicotine strategy. He is both a visionary and a pragmatist, and I have high expectations for—and full confidence in—what he will accomplish in his new role.”
Prior to joining PMI, Mr. Mishra was Managing Director, Portfolio Operations at Centerbridge Partners LP, a private equity firm, where, from 2014, he led commercial, operational, and digital transformations in investments in consumer services, renewable energy, and distribution sectors. Before Centerbridge, Mr. Mishra was a Partner at McKinsey & Company in London. At McKinsey & Company he was a member of the Consumer Goods, Retail, and Operations leadership teams from 2001 to 2014 and supported clients in the fast-moving consumer goods, retail, and private equity industries on commercial and operational transformations. Mr. Mishra started his career as a marketing professional with Procter & Gamble in 1996 and then spent four years at Accenture’s strategy practice in India and Eastern Europe. He holds an undergraduate degree in computer science from BITS Pilani in India and an MBA from the Indian Institute of Management (IIM) Lucknow.
Mr. Mishra’s direct reports will include Mario Masseroli, President, Latin America Region; Peter Luongo, Managing Director of Rothmans, Benson & Hedges (Canada); and Olek Grzesiak, Vice President, Commercial for Reduced Risk Products in the United States. The Washington, D.C.–based External Affairs team, led by attorney J.B. Simko, will report to Gregoire Verdeaux, Senior Vice President, External Affairs. Other corporate functions domiciled in the U.S. will continue to report to their corporate leads.
Martin King, who has been with PMI since 2003, most recently as CEO, PMI America, and before this as Chief Financial Officer, President of its Asia Region, President of its Latin America and Canada Region, and Senior Vice President of Operations, will retire on August 31, 2021. Prior to joining PMI, Mr. King served in various positions within Philip Morris USA—part of PMI’s former parent company—between 1991 and 2003. Mr. Olczak noted, “We are deeply grateful to Martin King for his many years and many accomplishments at PMI, and for the impact he has had in the U.S. in the year he spent getting the market ready for the push we plan to make in bringing both reduced-risk and, eventually, beyond nicotine products to consumers. Martin is an outstanding business leader and colleague, and we wish him the very best in the years to come.”
Also from July 1, PMI’s Strategy & Program Delivery function, which formerly reported to Mr. Mishra, will report to Chief Financial Officer Emmanuel Babeau. Ankur Modi will assume the position of Global Head, Strategy & Program Delivery. On August 1, Reginaldo Dobrowolski will take on the role of Vice President and Controller, and Andreas Kurali will become Deputy CFO, Finance Transformation.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders, and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS
Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS
and its consumables as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI’s smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS
and stopped smoking. For more information, please visit www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
